Thrivent Financial for Lutherans Invests $57,000 in Accuray Incorporated (NASDAQ:ARAY)

Thrivent Financial for Lutherans acquired a new stake in shares of Accuray Incorporated (NASDAQ:ARAY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 31,800 shares of the medical equipment provider’s stock, valued at approximately $57,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Renaissance Technologies LLC raised its stake in shares of Accuray by 0.3% during the 2nd quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock worth $5,118,000 after purchasing an additional 7,500 shares in the last quarter. Armistice Capital LLC bought a new position in Accuray during the second quarter valued at approximately $910,000. Bank of New York Mellon Corp lifted its stake in Accuray by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 279,426 shares of the medical equipment provider’s stock valued at $509,000 after acquiring an additional 8,864 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Accuray in the third quarter worth approximately $418,000. Finally, Assenagon Asset Management S.A. increased its stake in shares of Accuray by 127.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 164,999 shares of the medical equipment provider’s stock worth $297,000 after purchasing an additional 92,357 shares during the last quarter. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Stock Up 5.2 %

Shares of ARAY stock opened at $2.01 on Friday. The company has a market capitalization of $202.15 million, a price-to-earnings ratio of -11.82 and a beta of 1.44. The company has a debt-to-equity ratio of 3.59, a quick ratio of 0.87 and a current ratio of 1.63. The stock’s 50 day simple moving average is $1.89 and its 200 day simple moving average is $1.86. Accuray Incorporated has a twelve month low of $1.40 and a twelve month high of $3.05.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The business had revenue of $101.55 million during the quarter, compared to analysts’ expectations of $98.10 million. During the same period in the previous year, the company earned ($0.03) earnings per share. As a group, research analysts predict that Accuray Incorporated will post 0.01 EPS for the current year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.